691 related articles for article (PubMed ID: 19549260)
1. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
2. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.
Bruder JM; Ma JZ; Wing N; Basler J; Katselnik D
J Clin Densitom; 2006; 9(4):431-7. PubMed ID: 17097529
[TBL] [Abstract][Full Text] [Related]
3. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
[TBL] [Abstract][Full Text] [Related]
4. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
5. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
6. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
[TBL] [Abstract][Full Text] [Related]
7. Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients.
Deng JH; Yang LP; Wang LS; Zhou DF
Asian J Androl; 2004 Mar; 6(1):75-7. PubMed ID: 15064839
[TBL] [Abstract][Full Text] [Related]
8. [Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer].
Deng J; Li W; Yang L; Wang L; Zou D
Zhonghua Nan Ke Xue; 2004 Oct; 10(10):761-3. PubMed ID: 15562791
[TBL] [Abstract][Full Text] [Related]
9. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
Kawahara T; Kobayashi T; Nishizawa K; Kobori G; Mitsumori K; Ogura K
Hinyokika Kiyo; 2008 Apr; 54(4):261-6. PubMed ID: 18516917
[TBL] [Abstract][Full Text] [Related]
10. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
[TBL] [Abstract][Full Text] [Related]
11. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
Bruder JM; Ma JZ; Basler JW; Welch MD
Urology; 2006 Jan; 67(1):152-5. PubMed ID: 16413352
[TBL] [Abstract][Full Text] [Related]
13. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
Izumi K; Mizokami A; Sugimoto K; Narimoto K; Miwa S; Maeda Y; Kadono Y; Takashima M; Koh E; Namiki M
Urology; 2009 Jun; 73(6):1342-6. PubMed ID: 19371939
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
Morote J; Orsola A; Abascal JM; Planas J; Trilla E; Raventos CX; Cecchini L; Encabo G; Reventos J
J Urol; 2006 May; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
[TBL] [Abstract][Full Text] [Related]
15. Peripheral or axial bone density measurements to identify osteoporosis in prostate cancer patients undergoing androgen deprivation therapy?
Wadhwa VK; Parr NJ
Urology; 2009 Jun; 73(6):1347-51. PubMed ID: 19362345
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
17. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
[TBL] [Abstract][Full Text] [Related]
18. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
19. [Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism].
Yang LJ; Shen FX; Zheng JC; Zhang HL
Zhongguo Gu Shang; 2012 Feb; 25(2):133-7. PubMed ID: 22577718
[TBL] [Abstract][Full Text] [Related]
20. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]